Related Experiment Videos
In vivo-targeted gene delivery using antibody-based nonviral vector
Olivier Déas1, Eric Angevin, Claire Cherbonnier
1INSERM U542/Paris-Sud University, Bâtiment Lavoisier, 16 avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France.
Human Gene Therapy
|June 18, 2002
Summary
This study presents an improved nonviral gene delivery system using antibody-DNA noncovalent binding. The enhanced vector demonstrates superior gene transfer efficiency in tumor cells, both in vitro and in vivo.
Area of Science:
- Biotechnology
- Molecular Biology
- Oncology
Background:
- Tissue-specific gene transfer is challenging.
- Previous antibody-DNA conjugates had low nuclear translocation efficiency.
Purpose of the Study:
- To improve nonviral gene delivery efficiency.
- To develop a novel antibody-based vector for targeted gene transfer.
Main Methods:
- Utilized noncovalent binding with neutravidin and biotinylated components (antibody, fusogenic peptide, histone H1).
- Tested in vitro gene transfer in tumor cells and in vivo targeting of G250 antigen-positive tumors.
Main Results:
- Enhanced vector showed significantly higher reporter gene activity (15% vs. 0.5%) and interleukin 2 production in vitro.
- In vivo studies demonstrated specific beta-galactosidase expression in G250-positive tumors after intravenous injection.
Conclusions:
- The novel antibody-based vector effectively delivers genes to tumor cells.
- This improved system shows promise for targeted gene therapy applications.